NASDAQ:CLSN Imunon (CLSN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.95▼$2.6352-Week Range N/AVolume711 shsAverage Volume150,471 shsMarket Capitalization$13.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Imunon alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Imunon Stock (NASDAQ:CLSN)Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. CLSN Stock News HeadlinesMarch 10, 2024 | morningstar.comImunon Inc IMNNMay 22, 2023 | lse.co.ukCLSN.L Regulatory NewsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.October 9, 2022 | marketscreener.comCelsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate - Marketscreener.comOctober 3, 2022 | globenewswire.comImunon Reports Partial Results from Ongoing Non-human Primate Study - GlobeNewswireOctober 3, 2022 | globenewswire.comImunon Appoints James E. Dentzer to its Board of Directors - GlobeNewswireSeptember 29, 2022 | globenewswire.comImunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) - GlobeNewswireSeptember 28, 2022 | globenewswire.comIMUNON to Present at Chardan's 6th Annual Genetic Medicines - GlobeNewswireJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.September 19, 2022 | globenewswire.comCelsion Corporation Announces Company Name Change to Imunon, Inc. - GlobeNewswireSeptember 19, 2022 | finance.yahoo.comCelsion Corporation Announces Company Name Change to Imunon, Inc.September 15, 2022 | globenewswire.comCelsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer - GlobeNewswireSeptember 15, 2022 | finance.yahoo.comCelsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian CancerSeptember 12, 2022 | benzinga.comCelsion (NASDAQ:CLSN) – Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global I - BenzingaSeptember 12, 2022 | finance.yahoo.comCelsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13September 9, 2022 | benzinga.comCelsion (NASDAQ:CLSN) – Celsion Earnings Perspective: Return On Capital Employed - BenzingaSeptember 9, 2022 | msn.comCelsion Earnings Perspective: Return On Capital EmployedSeptember 7, 2022 | benzinga.comCelsionoration (CLSN) – Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investme - BenzingaSee More Headlines Receive CLSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/15/2022Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CLSN CUSIPN/A CIK749647 Webwww.celsion.com Phone(609) 896-9100Fax609-896-2200Employees27Year Founded1982Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,770,000.00 Net Margins-5,229.80% Pretax Margin-5,506.60% Return on Equity-50.18% Return on Assets-36.94% Debt Debt-to-Equity Ratio0.13 Current Ratio6.52 Quick Ratio6.52 Sales & Book Value Annual Sales$500,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.66 per share Price / BookN/AMiscellaneous Outstanding Shares7,099,000Free Float6,768,000Market Cap$13.91 million OptionableOptionable Beta2.27 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Michael H. Tardugno (Age 71)Exec. Chairman Comp: $1.01MMr. Jeffrey W. Church CPA (Age 65)CPA, CFO, Exec. VP & Corp. Sec. Comp: $528.54kDr. Khursheed Anwer M.B.A. (Age 62)Ph.D., Exec. VP & Chief Scientific Officer Comp: $511.92kDr. Nicholas Borys (Age 63)Exec. VP & Chief Medical Officer Comp: $586.54kDr. Corinne Le Goff M.B.A.Pharm.D., CEO, Pres & DirectorMr. Timothy J. Tumminello (Age 64)Chief Accounting Officer & Controller Ms. Marianne M. LambertsonVP of Communications & Investor RelationsMore ExecutivesKey CompetitorsRallybioNASDAQ:RLYBImmix BiopharmaNASDAQ:IMMXOcuphire PharmaNASDAQ:OCUPFortress BiotechNASDAQ:FBIODURECTNASDAQ:DRRXView All Competitors CLSN Stock Analysis - Frequently Asked Questions How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:CLSN) posted its earnings results on Monday, August, 15th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.12) by $0.25. Imunon had a negative trailing twelve-month return on equity of 50.18% and a negative net margin of 5,229.80%. When did Imunon's stock split? Imunon's stock reverse split before market open on Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Imunon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX) and ADMA Biologics (ADMA). This page (NASDAQ:CLSN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.